Sigenergy Showcases Next-Generation Energy Storage Solutions and Real-World Successes in Africa

JOHANNESBURG, Feb. 15, 2025 — Sigenergy, a leading energy solutions provider, held a Johannesburg event on February 14 showcasing its innovative commercial and industrial (C&I) energy storage systems. The event, attended by over 350 African energy professionals, featured a real-world example of Sigenergy’s technology resolving regional energy challenges and spurred…

New Viable Bone Allograft OraGen® Now Available for Dental Procedures “`

VIRGINIA BEACH, Va., Feb. 15, 2025 — LifeNet Health announces the market launch of OraGen®, a novel dental bone allograft. This cryopreserved corticocancellous bone allograft contains endogenous lineage-committed bone cells and demineralized bone matrix. This unique composition provides osteogenicity (bone cell production), osteoconductivity (a scaffold for cell growth), and osteoinduction…

RemeGen’s Disitamab Vedotin Plus Immunotherapy Shows Strong Phase II Results for Bladder Cancer at ASCO GU “`

YANTAI, China, Feb. 15, 2025 — At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, USA, Professor Xinan Sheng presented phase II trial data (NCT05297552, Study ID: RC48-C017) on Disitamab Vedotin (DV) plus Toripalimab as neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC).…